Erudio Healtherudio.com
Drug
IDRX-42 trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying IDRX-42: StrateGIST 3. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 1 more trial with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| StrateGIST 3 NCT07218926 · GlaxoSmithKline | metastatic and/or unresectable gastrointestinal stromal tumors after imatinib | Phase 3 | 84 | 17 | Focused | Oct 31, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| NCT05489237 NCT05489237 · IDRX, Inc., a wholly owned subsidiary of GSK, LLC FocusedView → | metastatic and/or unresectable gastrointestinal stromal tumors | Phase 1 | Focused | View | |||